CClinicalTrials.gg
Not yet recruitingNCT06148857Updated Nov 28, 2023

Total Corneal Astigmatism Prevalence in Cataract Patients

An observational study in Cataract, sponsored by Peking University Third Hospital. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Peking University Third Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Nov 2023, 2 years 11 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
11,000
Sex
All
01

Study summary

The purpose of this study is to report the prevalence data for total corneal astigmatism (TCA) in cataract surgery candidates.

Read the detailed description

The purpose of this retrospective study is to report the prevalence data for total corneal astigmatism (TCA) in cataract surgery candidates. Preoperative biometric data of all the patients who underwent cataract surgery in the Department of Ophthalmology, Peking University Third Hospital, from January 2019 to May 2023, were collected and analyzed. Data sets with incomplete biometric data were excluded.

02

Conditions studied

  • Cataract

Keywords

  • cataract
  • astigmatism
  • prevalence
03

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's planned enrollment of 11,000 is above the median of 81 across 484 observational studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All the patients who underwent cataract surgery in the Department of Ophthalmology, Peking University Third Hospital from January 2019 to May 2023.

Inclusion criteria

  • Patients who underwent cataract surgery in the Department of Ophthalmology, Peking University Third Hospital from January 2019 to May 2023.

Exclusion criteria

Exclusion Criteria:

  • Incomplete biometric data .
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
11,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testIOLMaster 700

    The IOLMaster 700, one of the most commonly used optical biometers for IOL power calculation, measures the anterior corneal surface radius using a telecentric keratometry. Additionally, it employs swept-source optical coherence tomography (SS-OCT) technology to simultaneously measures the posterior cornea surface radius and central corneal thickness (CCT). The AK formula, described by Abulafia et al., is a regression formula that calculates an estimated TCA using K astigmatism. The Barrett toric calculator uses an unpublished mathematical prediction method of TCA based on anterior corneal measurements.

    Also known as: the Abulafia-Koch formula, the Barrett toric calculator

06

What researchers measure

Primary outcomes

  1. total keratometric astigmatism

    Total keratometry is calculated based on the anterior and posterior corneal surface radius and CCT using the thick lens formula with the actual indices of refractions for air (1.000), cornea (1.376), and aqueous (1.336) by IOLMaster 700. Total keratometric astigmatism is taken as the TCA measured by IOLMaster 700.

    Time frame: At Enrollment

  2. Abulafia-Koch formula total corneal astigmatism

    The AK formula, described by Abulafia et al, is a regression formula that calculates an estimated TCA using K astigmatism.

    Time frame: At Enrollment

  3. Barrett toric calculator total corneal astigmatism

    The Barrett toric calculator uses an unpublished mathematical prediction method of TCA based on anterior corneal measurements. AL, ACD, LT, WTW, and K data by IOLMaster 700 were input into the Barrett toric calculator. The target refraction, incision surgically induced astigmatism (SIA), and incision location were all set as 0. The output net astigmatism was recorded as TCA predicted by the Barrett toric calculator.

    Time frame: At Enrollment

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06148857
Lead sponsor
Peking University Third Hospital
Responsible party
Sponsor
First posted
Nov 28, 2023
Start date
Nov 2023 (estimated)
Primary completion
Nov 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Nov 28, 2023

Study contacts

Hong Qi, Dr.
Contact
doctorgihong@163.com
+8613901066889 ext. 010
Hong Qi, Dr.
principal investigator · Peking University Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion